State Pharmaceutical Assistance Programs Still Cover What Medicare’s $2,100 Cap Doesn’t

9 min read · Last updated August 25, 2026

Dorothy Alvarez, 74, lives in Trenton, New Jersey, and pays $5 for a generic blood pressure prescription that costs $47 under her Medicare Part D plan alone. The difference comes from New Jersey’s Pharmaceutical Assistance to the Aged and Disabled program, a state benefit that still runs in 2026 even after Medicare capped total drug spending at $2,100 a year. Her program is one of a shrinking but real group of State Pharmaceutical Assistance Programs, often shortened to SPAPs. These programs pay for pieces of Part D drug costs the federal government still leaves on the table.

In this article

• What State Programs Still Cover That Extra Help and the Cap Don’t
• Pennsylvania, New York, and New Jersey: Three Programs Still Running in 2026
• A Worked Example: One New Jersey Senior’s Real Numbers
• What Changed Since the 2025 Redesign, and Why Massachusetts Is Winding Down
• How to Apply, and What to Do if Your State Isn’t Listed
• What Seniors Get Wrong About State Drug Assistance
• Frequently Asked Questions

What State Programs Still Cover That Extra Help and the Cap Don’t

Extra Help, also called the Part D Low-Income Subsidy, only reaches seniors with income at or below 150% of the federal poverty level, which is $23,940 a year for a single person in 2026. Above that line, Medicare’s new $2,100 annual out-of-pocket cap still applies, but a senior pays full monthly premiums and standard copays until they reach it. State Pharmaceutical Assistance Programs fill that middle band. Three states, Pennsylvania, New York, and New Jersey, still run active programs in 2026 that reach seniors earning two to three times the Extra Help limit. Each one pays for something the federal cap does not: the premium itself, a flat copay well below standard drug costs, or both.

Pennsylvania, New York, and New Jersey: Three Programs Still Running in 2026

Pennsylvania’s Pharmaceutical Assistance Contract for the Elderly program, called PACE, covers single residents earning $14,500 or less and married couples earning $17,700 or less. PACE pays a member’s Part D premium up to the 2026 regional benchmark of $32.71 a month and caps copays at $6 for generics and $9 for brand-name drugs. Its higher-income companion tier, the Pharmaceutical Assistance Contract for the Elderly Needs Enhancement Tier (PACENET), serves residents earning up to $33,500 for singles and $41,500 for couples, at $8 and $15 copays, but PACENET members pay their own Part D premium themselves, collected through the pharmacy along with their medication costs rather than covered by the state. A 2025 law, Act 49 of 2025, extends a cost-of-living adjustment (COLA) protection for both tiers through December 31, 2027, so a member who would otherwise be pushed over the income limit by a Social Security raise alone stays enrolled. This means a Pennsylvania senior who earns too much for Extra Help can still get capped copays through PACE or PACENET, a paid premium if they qualify for PACE specifically, and protection from a COLA-driven raise knocking them out of either program before 2028.

New York’s Elderly Pharmaceutical Insurance Coverage program, known as EPIC, reaches even further, covering singles earning up to $75,000 and married couples up to $100,000. EPIC splits members into two plans. On its Fee Plan, where members pay an annual fee of $8 to $300 based on income, EPIC pays a member’s Part D premium in full, up to the 2026 benchmark of $58.82 a month, regardless of income. On the Deductible Plan, where members’ deductibles range from $530 to $3,215 based on income, EPIC also pays that same $58.82 premium for singles earning up to $23,000 and couples up to $29,000. Deductible Plan members above that income pay their own premium, but EPIC lowers their annual deductible by roughly $706 to offset it. This means a New York senior on the Deductible Plan who earns too much for EPIC to pay their premium directly still gets real help through a reduced deductible.

New Jersey’s Pharmaceutical Assistance to the Aged and Disabled program, PAAD, covers singles earning under $54,943 and married couples under $62,390 in 2026. PAAD caps every covered prescription at $5 for generics or $7 for brand-name drugs, regardless of the drug’s actual price. It also pays the Part D premium for standard plans priced at or below the regional benchmark. This means a PAAD member’s copay never rises even if their medication costs hundreds of dollars a month.

A Worked Example: One New Jersey Senior’s Real Numbers

Consider a single New Jersey senior earning $40,000 a year, well within PAAD’s 2026 limit. Without any state help, Medicare’s cap limits her out-of-pocket drug spending to $2,100. She still owes her own Part D premium separately, often $40 to $50 a month, or roughly $480 to $600 a year. Add those together and her real annual cost lands near $2,600. PAAD changes that math directly. It pays her premium in full and caps every copay at $5 or $7. If she fills 12 prescriptions a year at the brand-name rate, her total cost drops to about $84, a savings of more than $2,500 in a single year.

State	Program	2026 Income Limit, Single	2026 Income Limit, Married	What It Pays
Pennsylvania	PACE / PACENET	$14,500 (PACE); $33,500 (PACENET)	$17,700 (PACE); $41,500 (PACENET)	Part D premium up to $32.71/month (PACE only; PACENET members pay their own through the pharmacy); copays of $6-$9 (PACE) or $8-$15 (PACENET) per 30-day supply; COLA protection through 2027 under Act 49 of 2025
New York	EPIC	$75,000	$100,000	Fee Plan: Part D premium paid up to $58.82/month regardless of income ($8-$300 annual fee). Deductible Plan: same premium paid up to $23,000 single/$29,000 married income; above that, member pays their own premium but gets a roughly $706 deductible reduction. Copays $3-$20.
New Jersey	PAAD	$54,943	$62,390	Flat $5 generic / $7 brand copay and Part D premium up to the regional benchmark

What Changed Since the 2025 Redesign, and Why Massachusetts Is Winding Down

Before 2025, Medicare Part D had a coverage gap, often called the donut hole, where seniors paid a much larger share of drug costs after an initial spending threshold. Several states built their pharmaceutical assistance programs specifically to close that gap. Once the federal government replaced the donut hole with a flat $2,000 cap in 2025, rising to $2,100 in 2026, some of those state programs lost most of their reason to exist. Massachusetts is the clearest case. Its Prescription Advantage program grew to more than 75,000 members at the end of its first year, but enrollment had fallen to just 75 members by 2026, with fewer than 10 still receiving an actual financial benefit. The state stopped accepting new applications on June 30, 2026, and the program closes entirely in July 2027, citing the federal cap as the direct cause. Not every state program shrank the same way. Pennsylvania, New York, and New Jersey kept theirs running because they still pay for things the federal cap never touched, especially the monthly premium.

How to Apply, and What to Do if Your State Isn’t Listed

Every state program listed here is administered by a state agency, not by Medicare.gov, so applications go through the state directly. Pennsylvania residents apply through the state Department of Aging at 1-800-225-7223. New York residents apply through the EPIC program directly, and enrollment can be completed online. New Jersey residents apply through the NJSave online application or by mailing a paper form to the Division of Aging Services. A senior already receiving full Extra Help should still check their state program. Some, like New York’s EPIC, waive their own fees entirely for Extra Help recipients while still adding drug coverage Extra Help does not include. For readers outside these three states, the National Council on Aging’s BenefitsCheckUp tool is a reasonable starting point. It is a screening tool, though, not the source for a state’s official dollar figures.

What Seniors Get Wrong About State Drug Assistance

The most common mistake is assuming Medicare’s new cap made these programs redundant, when in most cases it only reduced how much a state program has to cover. The second mistake is skipping the renewal notice. Pennsylvania and New Jersey both require periodic reapplication, and a missed renewal window can drop a senior back to full Part D pricing with no warning. The third mistake is assuming a program only helps with copays. New York’s EPIC, New Jersey’s PAAD, and Pennsylvania’s PACE all pay part or all of the Part D premium itself, a cost the federal cap never addresses at all.

Frequently asked questions

Do I still need a State Pharmaceutical Assistance Program if I already have Extra Help? Sometimes. Extra Help, the Part D Low-Income Subsidy, already covers most premium and copay costs for qualifying seniors. But some state programs, like New York’s EPIC, add coverage for drugs Part D excludes and waive their own fees for Extra Help recipients, so it is worth checking anyway.

What is the 2026 income limit for New Jersey’s PAAD program? New Jersey’s Pharmaceutical Assistance to the Aged and Disabled program covers single residents earning less than $54,943 a year. The limit for married couples is $62,390 a year in 2026, according to the state Division of Aging Services.

Does Pennsylvania’s PACE program pay my Medicare Part D premium? PACE does, up to the 2026 regional benchmark of $32.71 a month, in addition to capping copays at $6 to $9 per prescription. Its companion tier, PACENET, does not pay the premium. PACENET members pay their own Part D premium themselves, collected through the pharmacy along with their medication costs, while PACENET still caps copays at $8 to $15.

What happens if my state’s program is phasing out, like Massachusetts’s Prescription Advantage? Current members typically keep their benefits through the phase-out period, but new applications stop accepting well before the final closure date. Anyone in a winding-down program should confirm their Extra Help eligibility and Medicare Part D plan choice now, rather than waiting until the program closes.